Dr. Dennis Mulac

Dr. Dennis Mulac
© Dziemba

Lebensmittelchemiker, Akademischer Rat

Institut für Pharmazeutische Technologie und Biopharmazie
Corrensstr. 48
D - 48149 Münster

Raum C.110.157

Tel.: +49 (0)251 - 8339868
Fax: +49 (0)251 - 8339308
E-Mail: mulac.dennis (AT) uni-muenster (DOT) de

Forschung

  • Preise

    PHOENIX Pharmazie Wissenschaftspreis – PHOENIX group

  • Publikationen

    • Anderski J., Mahlert L., Mulac D., Langer K. „Photosensitizer-loaded nanoparticles: Promising drug delivery systems for photodynamic therapy of intestinal cancer?“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Keuth J., Mulac D., Langer K. „Challenges in development of EDTA-nanoparticles for therapy of calcification disorders.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Neufeld N., Mulac D., Langer K. „Genipin as a bioalternative crosslinker for the stabilization of HSA nanoparticles.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Partikel K., Korte R., Hoevelmann Y., Mulac D., Langer K. „Effect of different serum types on the formation of the nanoparticle-protein corona.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Backhaus S., Mulac D., Langer K. „Different strategies for the formation of blood-brain barrier crossing PLGA nanoparticles.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Gonnisen D, Mulac D, Söbbing J, Grünebaum J, Fuchs H, Langer K, Riehemann K. „Effects of PLGA nanoparticles on macrophages and cholangiocellular cancer cells. .“ contributed to the Nanobio europe 2014, Münster, .
    • Söbbing J, Grünebaum J, Mulac D, Langer K. „Are polymeric nanoparticles able to cross the gastrointestinal barrier?“ contributed to the DPhG Jahrestagung, Frankfurt, .
    • Gossmann R, Mulac D, Hummel M, Brockmeyer J, Langer K. „Cationic nanoparticles as promsing drug delivery system? In detail characterization of surface properties.“ contributed to the DPhG Jahrestagung, Frankfurt, .
    • Wessels L, Tacke S, Mulac D, Langer K. „Nanocapsules – Is the preparation of core-shell structured nanosystems that simple? .“ contributed to the DPhG Jahrestagung, Frankfurt, .
    • Grünebaum J, Söbbing J, Mulac D, Langer K. „Improved photocytotoxicity in cholangiocellular cell lines with mTHPP-loaded PLGA nanoparticles.“ contributed to the PBP World Meeting, Lissabon, .
    • Gossmann R, Mulac D, Langer K. „New perspective in the formulation and characterization of DMAB-stabilized PLGA nanoparticles.“ contributed to the PBP World Meeting, Lissabon, .
    • Söbbing J, Mulac D, Wieland G, Wiehe A, Langer K. „Preparation and physic-chemical evaluation of PLGA nanoparticles for photodynamic tumor therapy.“ contributed to the PBP World Meeting, Lissabon, .
    • Mulac D, Fahrländer E, Gossmann R, Langer K. „Comparative examination of adsorption of serum proteins on HSA and PLGA based nanoparticles.“ contributed to the PBP World Meeting, Lissabon, .
    • Söbbing J, Grünebaum J, Mulac D, Langer K. „Preparation and biological evaluation of mTHPP-loaded PLGA nanoparticles for photodynamic tumor therapy.“ contributed to the DPhG Jahrestagung, Freiburg, .
    • Grünebaum J, Söbbing J, Engel A, Mulac D, Langer K. „Methodische Voraussetzung zur Untersuchung der Permeabilität von Nanopartikeln am Caco-2 Modell. .“ präsentiert auf der Transportertage Bad Herrenalb, Bad Herrenalb, .
    • Mulac D, Grote AK, Kleigrewe K, Humpf HU. „Uptake and Metabolism of Ergot Alkaloids in Human Cells.“ contributed to the Mykotoxinworkshop, Freising, .
    • Mulac D, Hüwel S, Galla HJ, Humpf HU. „Einfluss von Mutterkornalkaloiden auf die Blut-Hirn-Schranke im in vitro Modellsystem.“ präsentiert auf der Treffen der Blut-Hirn-Schranke Experten und Caco-2 Anwender, Bad Herrenalb, .
    • Mulac D, Humpf HU. „Cytotoxic effects of ergot alkaloids on human primary cells.“ contributed to the Single Cell and Molecule Analysis, Münster, .
    • Mulac D, Königs M, Schwerdt G, Gekle M, Humpf HU. „Risk assessmentof T-2 and HT-2 toxin using human cells in primary culture.“ contributed to the SKLM, Kaiserslautern, .
    • Fraske A, Harrer H, Hübner F, Königs M, Mulac, D, Humpf, HU. „Large-scale Isolation and Purification of Fumonisins using Fast Centrifugal Partition Chromatography (FCPC).“ contributed to the Mykotoxinworkshop, Utrecht, .
    • Gossmann R., Hummel M., Mulac D., Brockmeyer J., Langer K. „Cationic nanoparticles. An analytical approach to biological relevance.“ contributed to the 1st European Conference on Pharmaceutics – Drug Delivery, Reims, France, .
    • Grünebaum J., Söbbing J., Mulac D., Langer K. . ‘Nanoparticulate carriers for photodynamic therapy of cholangiocarcinoma: In vitro comparison of various polymer-based nanoparticles.’ International Journal of Pharmaceutics 496, Nr. 2: 942–952. doi: 10.1016/j.ijpharm.2015.10.023.
    • Mulac D., Königs M., Schwerdt G., Gekle M., Humpf H. . ‘Safety Assessment of Botanicals and Botanical Preparations Used as Ingredients in Food Supplements: Testing an European Food Safety Authority-Tiered ApproachRisk Assessment of T-2 and HT-2 Toxin Using Human Cells in Primary Culture.’ In Risk Assessment of Phytochemicals in Food: Novel Approaches, edited by Wiley-Blackwell, 420. Wiley-Blackwell. doi: 10.1002/9783527634705.ch4.
    • Gossmann R., Langer K., Mulac D. . ‘New perspective in the formulation and characterization of didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles.’ PloS one 10, Nr. 7. doi: 10.1371/journal.pone.0127532.
    • Gossmann R., Fahrländer E., Hummel M., Mulac D., Brockmeyer J., Langer K. . ‘Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS.’ European journal of pharmaceutics and biopharmaceutics 93, Nr. null: 80–87. doi: 10.1016/j.ejpb.2015.03.021.
    • Mulac D, Grote AK, Kleigrewe K, Humpf HU. . ‘Investigation of the metabolism of ergot alkaloids in cell culture by fourier transformation mass spectrometry.’ Journal of Agricultural and Food Chemistry 59, Nr. 14: 7798. doi: 10.1021/jf2012024.
    • Mulac D, Lepski S, Ebert F, Schwerdtle T, Humpf HU. . ‘Cytotoxicity and fluorescence visualization of ergot alkaloids in human cell lines.’ Journal of Agricultural and Food Chemistry 61, Nr. 2: 462. doi: 10.1021/jf304569q.
    • Niehoff A.-C., Moosmann A., Söbbing J., Wiehe A., Mulac D., Wehe C.A., Reifschneider O., Blaske F., Wagner S., Sperling M., von Briesen H., Langer K., Karst U. . ‘A palladium label to monitor nanoparticle-assisted drug delivery of a photosensitizer into tumor spheroids by elemental bioimaging.’ Metallomics 6, Nr. 1: 77–81. doi: 10.1039/c3mt00223c.
    • Engel A., Ploger M., Mulac D., Langer K. . ‘Asymmetric flow field-flow fractionation (AF4) for the quantification of nanoparticle release from tablets during dissolution testing.’ International Journal of Pharmaceutics 461, Nr. 1: 137–144. doi: 10.1016/j.ijpharm.2013.11.044.
    • Mulac D, Hüwel S, Galla HJ, Humpf HU. . ‘Permeability of ergot alkaloids across the blood-brain barrier in vitro and influence on the barrier integrity.’ Molecular Nutrition and Food Research 56, Nr. 3: 475. doi: 10.1002/mnfr.201100431.
    • Mesken J., Iltsche A., Mulac D., Langer K. . ‘Modifying plasmid-loaded HSA-nanoparticles with cell penetrating peptides −cellular uptake and enhanced gene delivery .’ International Journal of Pharmaceutics 522: 198–209. doi: 10.1016/j.ijpharm.2017.03.006.
    • Lappe S., Mulac D., Langer K. . ‘Polymeric nanoparticles – Influence of the glass transition temperature on drug release.’ International Journal of Pharmaceutics 517, Nr. null: 338–347. doi: 10.1016/j.ijpharm.2016.12.025.
    • Raudszus B., Partikel K., Mulac D., Langer K. „Characterization and cellular uptake of polysorbate 80-coated PLA nanoparticles.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Partikel K, Korte R, Mulac D, Langer K. „Effect of nanoparticle size on the protein corona: A comparison between 100 and 200 nm PLGA nanoparticles.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Mesken J, Mulac D, Langer K. „Cell penetrating peptides as targeting ligands for nanoparticle based gene therapy – Influence on cellular uptake and transfection efficiency.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Anderski J., Mahlert L., Mulac D., Langer K. „PLGA-based nanoparticles for oral application of photosensitizers as photodynamic therapy to treat gastrointestinal cancer.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Niehoff A., Grünebaum J., Moosmann A., Mulac D., Söbbing J., Niehaus R., Buchholz R., Kröger S., Wiehe A., Wagner S., Sperling M., von Briesen H., Langer K., Karst U. . ‘Quantitative bioimaging of platinum group elements in tumor spheroids.’ Analytica Chimica Acta 938, Nr. null: 106–113. doi: 10.1016/j.aca.2016.07.021.
    • Mesken J., Mulac D., Langer K. „Non-viral gene therapy: Successful uptake and transfection efficiency by plasmid-loaded protein-nanoparticles modified with cell penetrating peptides .“ contributed to the PBP World Meeting, Glasgow, UK, .
    • Mahlert L., Anderski J., Mulac D., Langer K. „Overcoming the mucus barrier - in vitro evaluation of mucus permeating nanoparticles for PDT.“ contributed to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien, .
    • Anderski J., Mahlert L., Mulac D., Sun J., Birnbaum W., Kuckling D., Langer K. „Light-sensitive nanoparticles as innovative drug delivery systems for a controlled drug release.“ contributed to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien, .
    • Franz J., Grünebaum J., Schäfer M., Mulac D., Rehfeldt F., Langer K., Kramer A., Riethmüller C. . ‘Rhombic organization of microvilli domains found in a cell model of the human intestine.’ PloS one 13, Nr. 1. doi: 10.1371/journal.pone.0189970.
    • Mesken J., Iltzsche A., Mulac D., Langer K. . ‘EB1 modified HSA nanoparticles as non-viral delivery vectors-Influence of peptide concentration on cell uptake.’ Contributed to the 7. NRW Nano-Konferenz, Münster, Germany. doi: 10.1016/j.matpr.2017.09.183.
    • Gossmann R., Spek S., Langer K., Mulac D. . ‘Didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles: Uptake and cytotoxic potential in Caco-2 cells.’ Journal of Drug Delivery Science and Technology 43, Nr. null: 430–438. doi: 10.1016/j.jddst.2017.11.002.
    • Raudszus B., Partikel K., Mulac D., Langer K. . ‘Characterisation and cellular uptake of polysorbate 80-coated PLA nanoparticles.’ Contributed to the 7. NRW Nano-Konferenz, Münster, Germany. doi: 10.1016/j.matpr.2017.09.186.
    • Raudszus B., Mulac D., Langer K. . ‘A new preparation strategy for surface modified PLA nanoparticles to enhance uptake by endothelial cells.’ International Journal of Pharmaceutics 536, Nr. 1: 211–221. doi: 10.1016/j.ijpharm.2017.11.047.
    • Barth C., Mulac D., Langer K. „Influence of PEG spacer selection on active targeting of trastuzumab-modified nanoparticles.“ contributed to the DPhG Annual Meeting, Heidelberg, Germany, .
    • Alberding G., Mulac D., Langer K. „Surface modification of PLGA nanoparticles with cysteine for oral drug delivery.“ contributed to the DPhG Annual Meeting, Heidelberg, Germany, .
    • Wünsch A., Mulac D., Langer K. „Lipoprotein mimicking nanoparticles as colloidal drug delivery system.“ contributed to the DPhG Annual Meeting, Heidelberg, Germany, .
    • Wünsch A., Mulac D., Langer K. „Imitating lipoproteins as drug delivery system - Apolipoprotein E-modified lipid nanoparticles.“ contributed to the 21. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany, .
    • Backhaus S., Mulac D., Langer K. „Are PLGA-based glutathione-modified nanoparticles sufficient to cross the blood-brain barrier?“ contributed to the 21. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany, .
    • Alberding G., Mulac D., Langer K. „PLGA nanoparticles for oral drug delivery: Influence of polymer end groups and particle size on permeability in the Caco-2 model.“ contributed to the 21. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany, .
    • Backhaus S., Mulac D., Langer K. „Preparation and characterization of penetratin-modified PLGA nanoparticles for endothelial cellular uptake.“ contributed to the 3rd European Conference on Pharmaceutics – Bringing science into pharmaceutical practice, Bologna, Italy, .
    • Pieper S., Onafuye H., Mulac D., Cinatl J., Wass M.N. Michaelis M., Langer K. . ‘Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity.’ Beilstein J. Nanotechnol. 10: 2062–2072.
    • Onafuye H., Pieper S., Mulac D., Cinatl jr. J., Wass M.N., Langer K., Michaelis M. . ‘Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance.’ Beilstein J. Nanotechnol. 10: 1707–1715.
    • Sun J., Jung D., Schoppa T., Anderski J., Picker M.-T., Ren Y., Mulac D., Stein N., Langer K., Kuckling D. . ‘Light-responsive serinol-based poylcarbonate and polyester as degradable scaffolds.’ ACS Applied Bio Materials 2: 3038–3051.
    • Partikel K., Korte R., Stein N.C., Mulac D., Herrmann F.C., Humpf H.-U., Langer K. . ‘Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles.’ Eur. J. Pharm. Biopharm. 2019: 70–80.
    • Mahlert L., Anderski J., Schoppa T., Mulac D., Sun J., Kuckling D., Langer K. . ‘In vitro evaluation of innovative light-responsive nanoparticles for controlled drug release in intestinal PDT.’ Int. J. Pharm. 565: 199–208.
    • Partikel K., Korte R., Mulac D., Humpf H.-U., Langer K. . ‘Serum type and concentration both affecting the protein corona composition of PLGA nanoparticles.’ Beilstein J. Nanotechnol. 10: 1002–1015.
    • Mahlert L., Anderski J., Mulac D., Langer K. . ‘The impact of gastrointestinal mucus – new in vitro evaluation of promising mucus-penetrating PLGA-NP for photodynamic therapy in treatment of intestinal cancer.’ Eur. J. Pharm. Sci. 133: 28–39.
    • Anderski J., Mahlert L., Sun J., Birnbaum W., Mulac D., Schreiber S., Herrmann F., Kuckling D., Langer K. . ‘Light-responsive nanoparticles based on new polycarbonates as innovative drug delivery systems for photosensitizers in PDT.’ International Journal of Pharmaceutics 557: 182–191.
    • Wünsch A., Mulac D., Langer K. „New lipid nanoparticle system based on lipoproteins: Cholesteryl oleate as solid core with different coatings.“ contributed to the NRW Nano-Conference, Dortmund, Deutschland, .
    • Stein N.C., Mulac D., Hermann F.C., Langer K. „Preparation and characterization of protein-stabilized mTHPC nanosuspensions.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Partikel K., Mulac D., Langer K. „The time-dependent nanoparticle-protein corona.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Neufeld N., Mulac D., Langer K. „Genipin crosslinked HSA nanoparticles for gene therapy: Impact of the crosslinker on transfection efficiency.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Keuth J., Nitschke Y., Mulac D., Riehemann K., Rutsch F., Langer K. „Reversion of arterial calcification by elastin targeted nanoparticles.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Backhaus S., Mulac D., Langer K. „Improved cellular uptake of different polysorbate 80-coated PLGA nanoparticles.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Anderski J., Mahlert L., Mulac D., Langer K. „Promising nanoparticulate drug delivery systems based on light-cleavable polymers .“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Alberding G., Mulac D., Langer K. „PLGA nanoparticles for oral drug delivery: Know your basics to overcome the hurdles.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Wünsch A., Mulac D., Langer K. „Formation of colloidal particles by dialysis of mixed albumin solution with lecithin emulsion: Incompatibility or chance for a new lipid-based drug delivery system?“ contributed to the DPhG Annual Meeting 2018, Hamburg, Deutschland, .
    • Stein N.C., Mulac D., Herrmann F.C., Langer K. „Nanoparticle albumin-bound technology – Drug properties as a crucial aspect for an application.“ contributed to the DPhG Annual Meeting 2018, Hamburg, Deutschland, .
    • Partikel K., Mulac D., Langer K. „Compositional evolution of the nanoparticle-protein corona with increasing concentration of human serum.“ contributed to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien, .
    • Sun J., Birnbaum W., Anderski J., Picker M.-T., Mulac D., Langer K., Kuckling D. . ‘Use of light-degradable aliphatic polycarbonate nanoparticles as drug carrier for photosensitizer.’ Biomacromolecules 19: 4677–4690.
    • Anderski J., Mahlert L., Mulac D., Langer K. . ‘Mucus-penetrating nanoparticles: Promising drug delivery systems for the photodynamic therapy of intestinal cancer.’ European journal of pharmaceutics and biopharmaceutics 129: 1–9.
    • Schultheis J, Beckmann D, Mulac D, Müller L, Esselen M, Düfer M. . ‘Nrf2 activation protects mouse beta cells from glucolipotoxicity by restoring mitochondrial function and physiological redox balance.’ Oxidative medicine and cellular longevity 2019. doi: 10.1155/2019/7518510.
    • Wünsch A., Mulac D., Langer K. . ‘Lecithin coating as universal stabilization and functionalization strategy for nanosized drug carriers to overcome the blood-brain barrier.’ Int. J. Pharm. 593: 120146.
    • Wünsch A., Mulac D., Langer K. . ‘Lipoprotein imitating nanoparticles: Lecithin coating binds ApoE and mediates non-lysosomal uptake leading to transcytosis over the blood-brain barrier.’ Int. J. Pharm. 589: 119821.
    • Stein N.C., Mulac D., Fabian J., Herrmann F.C., Langer K. . ‘Nanoparticle albumin-bound mTHPC for photodynamic therapy: Preparation and comprehensive characterization of a promising drug delivery system.’ Int. J. Pharm. 582: 119347.
    • Keuth J., Nitschke Y., Mulac D., Riehemann K., Rutsch F., Langer K. . ‘Reversion of arterial calcification by elastin-targeted DTPA-HSA nanoparticles.’ Eur. J. Pharm. Biopharm. 150: 108–119.
    • Spreen H., Behrens M., Mulac D., Humpf H.U., Langer K. „Nanoparticle matrix and incubation medium – main influencer of the protein corona?“ contributed to the DPhG Annual Meeting, Leipzig online, .
    • Schoppa T., Mulac D., Rust T., Jung D., Kuckling D., Langer K. „New light-responsive polymeric nanoparticles as an on demand drug releasing system.“ contributed to the DPhG Annual Meeting, Leipzig online, .
    • Wünsch A., Mulac D., Langer K. „Nanoparticles inspired by lipoproteins: A lecithin stabilized and ApoE functionalized carrier system to overcome the blood-brain barrier.“ contributed to the DPhG Annual Meeting, Leipzig online, .
    • Wünsch A., Mulac D., Langer K. „ApoE-modified Lipid Nanoparticles Enclosing Different Core Variations to Overcome the Blood-Brain Barrier.“ contributed to the CRS Virtual Annual Meeting, online, .
    • Barth C., Spreen H., Mulac D., Keuter L., Behrens M., Humpf H.-U., Langer K. . ‘Spacer length and serum protein adsorption affect active targeting of trastuzumab-modified nanoparticles.’ Biomaterials and Biosystems 5: 100032. doi: 10.1016/j.bbiosy.2021.100032.
    • Schoppa T., Jung D., Rust T., Mulac D., Kuckling D., Langer K. . ‘Light-responsive nanoparticles based on a novel nitropiperonal derived polyester as drug delivery systems for photosensitizers in PDT.’ Int. J. Pharm. 597: 120326.
    • Spreen H., Behrens M., Mulac D., Humpf H., Langer K. . ‘Identification of main influencing factors on the protein corona composition of PLGA and PLA nanoparticles.’ European journal of pharmaceutics and biopharmaceutics 163: 212–222.
    • Barth, M.; Rudolph, S.; Kampschulze, J.; Meyer zu Vilsendorf, I.; Hanekamp, W.; Mulac, D.; Langer, K.; Lehr, M. . ‘Hexafluoroisopropyl carbamates as selective MAGL and dual MAGL/FAAH inhibitors: Biochemical and physicochemical properties.’ ChemMedChem 17: e2021007. doi: 10.1002/cmdc.202100757.
    • Subeska A; Voundi ME; Hanekamp W; Mulac D; Langer K; Lehr M. . ‘Synthesis, activity, metabolic stability and cell permeability of new cytosolic phospholipase A2α inhibitors with 1-indolyl-3-phenoxypropan-2-one structure.’ Bioorganic and Medicinal Chemistry Letters 92: 129374. doi: 10.1016/j.bmcl.2023.129374.
    • Subeska A; Althaus J; Hake T; Hanekamp W; Bettenworth D; Mulac D; Langer K; Lehr M. . ‘Synthesis and pharmacokinetic properties of novel cPLA2α inhibitors with 1-(carboxyalkylpyrrolyl)-3-aryloxypropan-2-one structure.’ Bioorganic and Medicinal Chemistry 77: 117110. doi: 10.1016/j.bmc.2022.117110.
    • Adick A.; Hoheisel W.; Schneid S.; Mulac D.; Azhdari S.; Langer K. . ‘Challenges of nanoparticle albumin bound (nab™) technology: Comparative study of Abraxane® with a newly developed albumin-stabilized itraconazole nanosuspension.’ European journal of pharmaceutics and biopharmaceutics 193: 129–143. doi: 10.1016/j.ejpb.2023.10.022.
    • Hester S.; B. Ferenz K.; Adick A.; Kakalias C.; Mulac D.; Azhdari S.; Langer K. . ‘Triglyceride-filled albumin-based nanocapsules: A promising new system to avoid discarding poorly water-soluble drug candidates.’ International Journal of Pharmaceutics 646. doi: 10.1016/j.ijpharm.2023.123454.
    • Linß, F.; Mulac, D.; Langer, K. „Thiol groups on nanoparticle surfaces promote unspecific cell interaction in targeting studies.“ contributed to the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Rotterdam, .
    • Prell, K.; Mulac, D.; Langer, K. „Collagen gels as a support for cell barriers - Investigation of nanoparticle permeation.“ contributed to the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Rotterdam, .
    • Spreen, H.; Mulac, D.; Langer, K. „Characterization of nanoparticle-bound trastuzumab adsorption behavior and its cellular interaction.“ contributed to the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Rotterdam, .
    • Adick, A.; Hoheisel, W.; Schneid, S.; Mulac, D.; Herrmann, F.; Langer, K. „A closer look at nab™ technology: Systematic characterization of Abraxane®.“ contributed to the DPhG Annual Meeting, Marburg, .
    • Laabs, M.; Mulac, D.; Langer, K.; Wünsch, A. „Different strategies to formulate flurbiprofen in PEGylated lipid-polymer hybrid nanoparticles carrying it across the blood-brain barrier.“ contributed to the DPhG Annual Meeting, Marburg, .
    • Linß, F.; Mulac, D.; Riehemann, K.; Langer, K. „Achieving specific vascular targeting of antibody-linked albumin nanoparticles in a pulsatile shear force model.“ contributed to the DPhG Annual Meeting, 2022, .
    • Prell, K.; Mulac, D.; Langer, K. „Collagen gels as a support for cell barriers - Investigation of nanoparticle permeation.“ contributed to the DPhG Annual Meeting, Marburg, .
    • Tran, X.; Mulac, D.; Langer, K. „Selective targeting of Trastuzumab-bound nanoparticles to HER2/neu-positive SK-Br-3 cells in the presence of non-target MCF-7 cells.“ contributed to the DPhG Annual Meeting, Marburg, .
    • Laabs, M.; Mulac, D.; Wünsch, A.; Langer, K. „New lipid-polymer hybrid nanoparticles loaded with flurbiprofenaxetil and coated with apolipoprotein E – A game changer in Alzheimer´s treatment?“ contributed to the 4th European Conference on Pharmaceutics, Marseille, .
    • Prell, K.; Mulac, D.; Langer, K. „Ion pairing approach to influence release kinetics of loperamide loaded polymeric nanoparticles and investigation of their behavior at the blood brain barrier.“ contributed to the 4th European Conference on Pharmaceutics, Marseille, .
    • Hester, S.; Ferenz, K.B.; Mulac, D.; Kakalias, C.; Langer, K. „Triglyceride-filled albumin nanocapsules: A new possibility to formulate poorly water-soluble drug candidates.“ contributed to the NRW Nanokonferenz, Dortmund, .
    • Laabs, M.; Mulac, D.; Wünsch, A.; Langer, K. „Lipoprotein imitating nanoparticles targeting LRP1 – A promising pathway to cross the blood-brain barrier?“ contributed to the 22. Barriere- und Transporter-Days, Bad Herrenalb, .
    • Adick, A.; Hoheisel, W.; Schneid, S.; Mulac, D.; Langer, K. „The nanoparticle albumin bound technology: Formulation of poorly water-soluble drugs for intravenous use.“ contributed to the DPhG Annual Meeting, Tübingen, .
    • Kramer, M.; Völlmecke, K.; Mulac, D.; Kuckling, D.; Langer, K. „Preparation of stimulus responsive nanoparticles: A comparative study of lab techniques and microfluidics.“ contributed to the DPhG Annual Meeting, Tübingen, .
    • Laabs, M.; Mulac, D.; Wünsch, A.; Langer, K. „Nature as a model: Using phospholipids as coating material for lipid nanoparticles to imitate natural lipoproteins.“ contributed to the DPhG Annual Meeting, Tübingen, .
    • Lins, A.; Keuter, L.; Mulac, D.; Humpf; H.-U.; Langer, K. „Role of stabilizers in protein adsorption patterns of PLGA nanoparticles.“ contributed to the DPhG Annual Meeting, Tübingen, .
    • Tran, X.; Mulac, D.; Langer, K. „More advanced cell culture models to investigate the selective targeting of trastuzumab-bound nanoparticles to HER2/neu-positive cells.“ contributed to the DPhG Annual Meeting, Tübingen, .
    • Feldmann, Anja; Nitschke, Yvonne; Linss, Franziska; Mulac, Dennis; Stuecker, Sina; Bertrand, Jessica; Buers, Insa; Langer, Klaus; Rutsch, Frank. . ‘Improved Reversion of Calcifications in Porcine Aortic Heart Valves Using Elastin-Targeted Nanoparticles.’ International Journal of Molecular Sciences (IJMS) 24, Nr. 22. doi: 10.3390/ijms242216471.

  • Vorträge

    • Anderski, Juliane; Mahlert, Laura (): ‘Interactions of nanoparticles with mucus - the first barrier before reaching intestinal cells’. Bad Herrenalber Transporter- und Barrieretage (Steinbeis Transferzentrum Biopharmazie und Analytik, Vertreten durch Gerd Fricker), Bad Herrenalb, Deutschland, .
    • Raudszus, Bastian; Mulac, Dennis; Langer, Klaus (): ‘Apo E-modification of PLA-nanoparticles enhances cellular uptake into brain endothelium’. 10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Glasgow, Vereinigtes Königreich, .

Lehre

Lehre:

Praktikum "Pharmazeutische Technologie einschließlich Medizinprodukte" :

  • Feste Arzneiformen
  • Moderne Arzneiformen